Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Cyclin-Dependent Kinase 2 in Cellular Senescence and Cancer. A Structural and Functional Review

View through CrossRef
<P>Background: Cyclin-dependent kinase 2 (CDK2) has been studied due to its role in the cell-cycle progression. The elucidation of the CDK2 structure paved the way to investigate the molecular basis for inhibition of this enzyme, with the coordinated efforts combining crystallography with functional studies. </P><P> Objective: Our goal here is to review recent functional and structural studies directed to understanding the role of CDK2 in cancer and senescence. </P><P> Methods: There are over four hundreds of crystallographic structures available for CDK2, many of them with binding affinity information. We use this abundance of data to analyze the essential features responsible for the inhibition of CDK2 and its function in cancer and senescence. </P><P> Results: The structural and affinity data available CDK2 makes it possible to have a clear view of the vital CDK2 residues involved in molecular recognition. A detailed description of the structural basis for ligand binding is of pivotal importance in the design of CDK2 inhibitors. Our analysis shows the relevance of the residues Leu 83 and Asp 86 for binding affinity. The recent findings revealing the participation of CDK2 inhibition in senescence open the possibility to explore the richness of structural and affinity data for a new era in the development of CDK2 inhibitors, targeting cellular senescence. </P><P> Conclusion: Here, we analyzed structural information for CDK2 in combination with inhibitors and mapped the molecular aspects behind the strongest CDK2 inhibitors for which structures and ligandbinding affinity data were available. From this analysis, we identified the significant intermolecular interactions responsible for binding affinity. This knowledge may guide the future development of CDK2 inhibitors targeting cancer and cellular senescence.</P>
Title: Cyclin-Dependent Kinase 2 in Cellular Senescence and Cancer. A Structural and Functional Review
Description:
<P>Background: Cyclin-dependent kinase 2 (CDK2) has been studied due to its role in the cell-cycle progression.
The elucidation of the CDK2 structure paved the way to investigate the molecular basis for inhibition of this enzyme, with the coordinated efforts combining crystallography with functional studies.
</P><P> Objective: Our goal here is to review recent functional and structural studies directed to understanding the role of CDK2 in cancer and senescence.
</P><P> Methods: There are over four hundreds of crystallographic structures available for CDK2, many of them with binding affinity information.
We use this abundance of data to analyze the essential features responsible for the inhibition of CDK2 and its function in cancer and senescence.
</P><P> Results: The structural and affinity data available CDK2 makes it possible to have a clear view of the vital CDK2 residues involved in molecular recognition.
A detailed description of the structural basis for ligand binding is of pivotal importance in the design of CDK2 inhibitors.
Our analysis shows the relevance of the residues Leu 83 and Asp 86 for binding affinity.
The recent findings revealing the participation of CDK2 inhibition in senescence open the possibility to explore the richness of structural and affinity data for a new era in the development of CDK2 inhibitors, targeting cellular senescence.
</P><P> Conclusion: Here, we analyzed structural information for CDK2 in combination with inhibitors and mapped the molecular aspects behind the strongest CDK2 inhibitors for which structures and ligandbinding affinity data were available.
From this analysis, we identified the significant intermolecular interactions responsible for binding affinity.
This knowledge may guide the future development of CDK2 inhibitors targeting cancer and cellular senescence.
</P>.

Related Results

Abstract A16: Wnt antagonist SFRP1 functions as secreted mediator of senescence
Abstract A16: Wnt antagonist SFRP1 functions as secreted mediator of senescence
Abstract The purpose of this study was 1) to identify the mediator(s) of senescence that are secreted from senescent cells and induce senescence in an autocrine and ...
Abstract 2842: 5-aza-2’-Deoxycytidine induces cellular senescence in non-small cell lung cancer
Abstract 2842: 5-aza-2’-Deoxycytidine induces cellular senescence in non-small cell lung cancer
Abstract Background: Lung cancer is one of the refractory malignancies and the leading cause of cancer-related death worldwide. Although prognosis of lung cancer was...
The role of senescence in cancer therapy-associated cardiovascular toxicity
The role of senescence in cancer therapy-associated cardiovascular toxicity
Cardiovascular diseases (CVDs) and cancer are the two leading causes of global mortality. Cancer treatments, including radiotherapy and chemotherapy, can have severe cardiotoxic si...
Initiation of Cyclin B Degradation by the 26S Proteasome upon Egg Activation
Initiation of Cyclin B Degradation by the 26S Proteasome upon Egg Activation
Immediately before the transition from metaphase to anaphase, the protein kinase activity of maturation or M-phase promoting factor (MPF) is inactivated by a mechanism that involve...
Two-Step Mechanism of Cyclin B Degradation Initiated by Proteolytic Cleavage with the 26 S Proteasome in Fish
Two-Step Mechanism of Cyclin B Degradation Initiated by Proteolytic Cleavage with the 26 S Proteasome in Fish
AbstractTo complete meiosis II, cyclin B is degraded in a short period by the inactivation of M-phase promoting factor (MPF). Previously, we showed that the destruction of cyclin B...
Data from MDM2 Controls the Timely Expression of Cyclin A to Regulate the Cell Cycle
Data from MDM2 Controls the Timely Expression of Cyclin A to Regulate the Cell Cycle
<div>Abstract<p>Overexpression of MDM2 has been related to oncogenesis. In this communication, we present evidence to show that MDM2 controls the cell cycle–dependent e...

Back to Top